 |
Pharmacyclics Announces Presentation of Preliminary Results From Phase 2 Clinical Trial of Xcytrin(R) With Radiosurgery for Brain Metastases
Nov 9, 2006
|
12.6 KB |
|
| |
SUNNYVALE, Calif., Nov 09, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced the presentation of preliminary results of an open-label multi-center Phase 2 clinical trial, which suggest that Xcytrin(R) (motexafin gadolinium) Injection may improve stereotactic radiosurgery treatment-planning by ...
|
|
Pharmacyclics Announces Pricing of Common Stock Offering
Nov 7, 2006
|
8.1 KB |
|
| |
SUNNYVALE, Calif., Nov 07, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced the pricing of an underwritten public offering of 4,200,000 shares of its common stock at a price to the public of $4.75 per share. The net proceeds of the offering after deducting underwriting discounts and commissio...
|
|
Pharmacyclics Announces Proposed Public Offering of Common Stock
Oct 30, 2006
|
7.9 KB |
|
| |
SUNNYVALE, Calif., Oct 30, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) announced today that it is offering to sell, subject to market and other conditions, 3,809,524 shares of its common stock pursuant to an effective registration statement in a public offering. All of the shares are being offered by Ph...
|
|
Pharmacyclics Reports First Quarter Financial Results
Oct 26, 2006
|
16.6 KB |
|
| |
SUNNYVALE, Calif., Oct 26, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today reported financial results for its first fiscal quarter ended September 30, 2006. The net loss for the first quarter of fiscal 2007, as reported in accordance with U.S. generally accepted accounting principles (GAAP) was $6.5 m...
|
|
Pharmacyclics Announces Conference Call to Discuss First Quarter 2007 Financial Results
Oct 24, 2006
|
8.5 KB |
|
| |
SUNNYVALE, Calif., Oct 24, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced that it will hold a conference call to discuss its first quarter 2007 financial results and achievements on Thursday, October 26, 2006, at 4:30 p.m. EDT (1:30 p.m. PDT).
To participate in the conference call, plea...
|
|
Pharmacyclics to Present at Thomas Weisel Partners Healthcare Conference 2006
Aug 30, 2006
|
8.4 KB |
|
| |
SUNNYVALE, Calif., Aug 30, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) announced today that Richard A. Miller, M.D., president and chief executive officer, is scheduled to present a corporate overview at the Thomas Weisel Partners Healthcare Conference 2006 at 4:25 p.m. EDT on Wednesday, September 6th a...
|
|
Pharmacyclics Reports Fourth Quarter and Fiscal 2006 Financial Results
Aug 24, 2006
|
20.0 KB |
|
| |
SUNNYVALE, Calif., Aug 24, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today reported financial results for its fourth quarter and fiscal year ended June 30, 2006. The net loss for the fourth quarter of fiscal 2006, as reported in accordance with U.S. generally accepted accounting principles (GAAP), was...
|
|
Pharmacyclics Secures Equity Financing Commitment
Aug 21, 2006
|
8.7 KB |
|
| |
SUNNYVALE, Calif., Aug 21, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced that it has received a commitment for up to $20 million in common stock equity financing from Azimuth Opportunity Ltd. Over the next eighteen months, Pharmacyclics may at its discretion, from time to time, sell regist...
|
|
Pharmacyclics Announces Conference Call to Discuss 2006 Year-end Results
Aug 16, 2006
|
7.7 KB |
|
| |
SUNNYVALE, Calif., Aug 16, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced that it will hold a conference call to discuss its 2006 year-end financial results and achievements, and 2007 guidance on Thursday, August 24, 2006, at 4:30 p.m. EDT (1:30 p.m. PDT).
To participate in the conferen...
|
|
Pharmacyclics Announces Termination of Stockholder Rights Plan Effective August 18, 2006
Aug 11, 2006
|
7.4 KB |
|
| |
SUNNYVALE, Calif., Aug 11, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) announced today that the company's board of directors approved the termination of the company's stockholder rights plan, commonly referred to as a "poison pill," which was originally scheduled to expire on April 30, 2007. The stockho...
|
|
Pharmacyclics Announces Additions to Board of Directors
Aug 9, 2006
|
10.1 KB |
|
| |
SUNNYVALE, Calif., Aug 09, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced the appointment of James L. Knighton and Christine A. White, M.D., to its board of directors. The board of directors also approved an increase in the size of the board from six to eight members.
The addition of Mr...
|
|
Pharmacyclics to Present at Pacific Growth Equities 2006 Life Sciences Growth Conference
Jun 8, 2006
|
7.5 KB |
|
| |
SUNNYVALE, Calif., June 8, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) announced today that Richard A. Miller, M.D., president and chief executive officer, is scheduled to present a corporate overview at the Pacific Growth Equities 2006 Life Sciences Growth Conference at 9:30 a.m. PDT on Wednesday, Jun...
|
|
Pharmacyclics Additional Data and New Analyses From Pivotal Phase 3 SMART Trial Presented at ASCO 2006
Jun 3, 2006
|
15.6 KB |
|
| |
SUNNYVALE, Calif., June 3, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced that additional new data and analyses supporting the company's decision to file a New Drug Application (NDA) for Xcytrin(R) (motexafin gadolinium) Injection, were presented at the 2006 Annual Meeting of the American ...
|
|
Pharmacyclics Announces Presentations and Published Abstracts on Xcytrin at The 2006 American Society of Clinical Oncology Annual Meeting
May 25, 2006
|
12.7 KB |
|
| |
SUNNYVALE, Calif., May 25, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) announced today multiple presentations and published abstracts regarding Xcytrin(R) (motexafin gadolinium) Injection, including an oral presentation of Phase 3 SMART (Study of Neurologic Progression with Motexafin Gadolinium And Rad...
|
|
Pharmacyclics to Submit New Drug Application for Xcytrin(R) for Treatment of Lung Cancer Patients With Brain Metastases
May 9, 2006
|
11.1 KB |
|
| |
SUNNYVALE, Calif., May 9, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced that the company plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) to market Xcytrin(R) (motexafin gadolinium) Injection for the treatment of non-small cell lung cancer (NSCLC...
|
|
Pharmacyclics Reports Third Quarter Financial Results
Apr 27, 2006
|
14.5 KB |
|
| |
SUNNYVALE, Calif., April 27, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today reported financial results for its third fiscal quarter ended March 31, 2006. The net loss for the third quarter of fiscal 2006, as reported in accordance with U.S. generally accepted accounting principles (GAAP), was $7.4 m...
|
|
Celera Genomics Announces Sale of Therapeutic Programs to Pharmacyclics
Apr 10, 2006
|
13.9 KB |
|
| |
ROCKVILLE, Md. and SUNNYVALE, Calif., April 10, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Celera Genomics (NYSE: CRA), an Applera Corporation business, and Pharmacyclics (Nasdaq: PCYC) today announced that Pharmacyclics has acquired multiple small molecule drug candidates for the treatment of cancer and other diseases from Celera Geno...
|
|
Pharmacyclics Reports Second Quarter Financial Results
Jan 26, 2006
|
13.7 KB |
|
| |
SUNNYVALE, Calif., Jan 26, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today reported financial results for its second fiscal quarter ended December 31, 2005. The net loss for the second quarter of fiscal 2006, as reported in accordance with U.S. generally accepted accounting principles (GAAP), was $9....
|
|
Pharmacyclics Announces Results from Phase 3 Smart Trial of Xcytrin(R) for Lung Cancer Brain Metastases
Dec 19, 2005
|
11.9 KB |
|
| |
SUNNYVALE, Calif., Dec 19, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced top-line results from its pivotal Phase 3 clinical study of Xcytrin(R) (motexafin gadolinium) Injection, for the potential treatment of non-small cell lung cancer (NSCLC) patients with brain metastases (i.e. lung can...
|
|
Pharmacyclics Announces Conference Call on Monday December 19 at 8:30 am Eastern Time to Discuss Xcytrin Phase 3 Results
Dec 18, 2005
|
9.0 KB |
|
| |
SUNNYVALE, Calif., Dec 18, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced that it will hold a conference call on Monday, December 19, 2005 at 8:30 a.m. Eastern Time to discuss top-line results from its pivotal Phase 3 clinical trial of Xcytrin(R) (motexafin gadolinium) Injection for the po...
|
|
|
